Forex Товарный рынок Фондовый рынок Криптовалюта
Amgen sees no bone safety concerns around experimental obesity drug

Amgen sees no bone safety concerns around experimental obesity drug

(Reuters) - Amgen (NASDAQ:AMGN ) said on Wednesday it does not see any bone safety concerns around the use of its experimental obesity drug, a day after data from an early-stage study dragged its stock 7% lower.

Source: Investing.com

Последние публикации
Nissan seeks investor to replace some of Renault's equity holding, FT reports
26.11.2024 - 08:00
Walmart to roll back some diversity policies amid pressure from conservatives
26.11.2024 - 08:00
Google proposes fresh tweaks to search results in Europe
26.11.2024 - 08:00
Dollar climbs, stocks retreat after Trump vows tariffs
26.11.2024 - 08:00
Disney settles suit over women's pay for $43 million
26.11.2024 - 08:00
Roche to acquire US firm Poseida Therapeutics in $1.5 billion deal
26.11.2024 - 08:00
Asia stocks fall after Trump threatens tariffs, Japan's Nikkei leads losses
26.11.2024 - 07:00
Japan stocks eye strong 2025 amid limited tariff impact- BofA
26.11.2024 - 07:00
Adani Green Energy says no talks on new financial commitment with TotalEnergies
26.11.2024 - 07:00
Tesla would likely be excluded from new California EV tax credits -governor's office says
26.11.2024 - 07:00
Citigroup slashes promotions as it seeks to overhaul bank, FT reports
26.11.2024 - 07:00
Asia stocks fall after Trump threatens tariffs, Japan's Nikkei lead losses
26.11.2024 - 06:00
Japan authorities raid Amazon Japan on alleged antitrust practices - Reuters
26.11.2024 - 06:00
Rivian gets conditional approval for $6.6 bln govt loan to build Georgia factory
26.11.2024 - 06:00
Rivian gets $6.6 billion conditional loan approval to build Georgia EV plant
26.11.2024 - 06:00

© Analytic DC. All Rights Reserved.

new
Анализ рынка Как повлият завтра отчет NFP на курс доллара США?